Takeda Completes Sale of Select OTC and Non-Core Assets to STADA

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to STADA Arzneimittel AG (“STADA”) for a total value of $660 million USD. The portfolio includes approximately 20 over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda’s Growth ...

Takeda Completes Sale of Select OTC and Non-Core Assets to STADA

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to STADA Arzneimittel AG (“STADA”) for a total value of $660 million USD. The portfolio includes approximately 20 over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda’s Growth ...

Takeda Completes Sale of Select OTC and Non-Core Assets to STADA

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to STADA Arzneimittel AG (“STADA”) for a total value of $660 million USD. The portfolio includes approximately 20 over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda’s Growth ...

Takeda Completes Sale of Select OTC and Non-Core Assets to STADA

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to STADA Arzneimittel AG (“STADA”) for a total value of $660 million USD. The portfolio includes approximately 20 over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda’s Growth ...

아이데미아, JAC와 손잡고 일본 레벨파이브 스타디움서 모포웨이브 콤팩트 개념증명 시행

글로벌 증강 신원확인 업계를 선도하는 아이데미아(IDEMIA)가 재팬 에어로스페이스 코퍼레이션(Japan Aerospace Corporation, 이하 ‘JAC’)과 파트너십을 맺고 ‘모포웨이브 콤팩트(MorphoWave™ Compact)’ 콘셉트의 POC(proof of concept, 개념증명)를 시행했다. 모포웨이브 콤팩트는 수상 이력이 빛나는 접근통제용 생체측정 기기이다. 아이데미아는 2019년 말 일본 후쿠오카 레벨파이브 스타...

아이데미아, JAC와 손잡고 일본 레벨파이브 스타디움서 모포웨이브 콤팩트 개념증명 시행

글로벌 증강 신원확인 업계를 선도하는 아이데미아(IDEMIA)가 재팬 에어로스페이스 코퍼레이션(Japan Aerospace Corporation, 이하 ‘JAC’)과 파트너십을 맺고 ‘모포웨이브 콤팩트(MorphoWave™ Compact)’ 콘셉트의 POC(proof of concept, 개념증명)를 시행했다. 모포웨이브 콤팩트는 수상 이력이 빛나는 접근통제용 생체측정 기기이다. 아이데미아는 2019년 말 일본 후쿠오카 레벨파이브 스타...

아이데미아, JAC와 손잡고 일본 레벨파이브 스타디움서 모포웨이브 콤팩트 개념증명 시행

글로벌 증강 신원확인 업계를 선도하는 아이데미아(IDEMIA)가 재팬 에어로스페이스 코퍼레이션(Japan Aerospace Corporation, 이하 ‘JAC’)과 파트너십을 맺고 ‘모포웨이브 콤팩트(MorphoWave™ Compact)’ 콘셉트의 POC(proof of concept, 개념증명)를 시행했다. 모포웨이브 콤팩트는 수상 이력이 빛나는 접근통제용 생체측정 기기이다. 아이데미아는 2019년 말 일본 후쿠오카 레벨파이브 스타...

아이데미아, JAC와 손잡고 일본 레벨파이브 스타디움서 모포웨이브 콤팩트 개념증명 시행

글로벌 증강 신원확인 업계를 선도하는 아이데미아(IDEMIA)가 재팬 에어로스페이스 코퍼레이션(Japan Aerospace Corporation, 이하 ‘JAC’)과 파트너십을 맺고 ‘모포웨이브 콤팩트(MorphoWave™ Compact)’ 콘셉트의 POC(proof of concept, 개념증명)를 시행했다. 모포웨이브 콤팩트는 수상 이력이 빛나는 접근통제용 생체측정 기기이다. 아이데미아는 2019년 말 일본 후쿠오카 레벨파이브 스타...

IDEMIA Partners With JAC to Successfully Test Frictionless Biometric Access Technology at Level5 Stadium in Japan

IDEMIA, the global leader in Augmented Identity and Japan Aerospace Corporation (JAC) partnered to demonstrate a proof of concept with MorphoWave™ Compact, a unique award-winning access control biometric device. A first in Japan, the biometric access technology was successfully tested at Level5 stadium in Fukuoka during the final match of the J2 League between Avispa Fukuoka and Kagoshima United Football Club at the end of 2019. MorphoWave™ Compact enables four fingerprints to be read ...

IDEMIA Partners With JAC to Successfully Test Frictionless Biometric Access Technology at Level5 Stadium in Japan

IDEMIA, the global leader in Augmented Identity and Japan Aerospace Corporation (JAC) partnered to demonstrate a proof of concept with MorphoWave™ Compact, a unique award-winning access control biometric device. A first in Japan, the biometric access technology was successfully tested at Level5 stadium in Fukuoka during the final match of the J2 League between Avispa Fukuoka and Kagoshima United Football Club at the end of 2019. MorphoWave™ Compact enables four fingerprints to be read ...